DAX23.667 +0,2%ESt505.465 -0,1%Top 10 Crypto15,94 +4,5%Dow46.170 -0,3%Nas22.493 -0,4%Bitcoin97.110 +2,4%Euro1,1736 -0,7%Öl69,20 +2,1%Gold3.734 -0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Gerresheimer A0LD6E Plug Power A1JA81 Alibaba A117ME D-Wave Quantum A3DSV9 Tesla A1CX3T Volkswagen (VW) vz. 766403 Deutsche Telekom 555750 Novo Nordisk A3EU6F DroneShield A2DMAA Amazon 906866 BYD A0M4W9 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt leicht im Pllus -- uniQure mit Durchbruch bei Huntington-Therapie -- SoftBank und Oracle wollen KI-Infrastruktur ausbauen -- Micron, D-Wave, Droneshield, BYD, Disney im Fokus
Top News
Tesla-Aktie: Basismodell des Cybertruck gestrichen - Einstiegspreis steigt deutlich an Tesla-Aktie: Basismodell des Cybertruck gestrichen - Einstiegspreis steigt deutlich an
Aufwärtspotenzial im Blick: Warum die Amazon-Aktie der Top Pick für Morgan Stanley ist Aufwärtspotenzial im Blick: Warum die Amazon-Aktie der Top Pick für Morgan Stanley ist
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
123,20 EUR -0,10 EUR -0,08 %
FSE
147,22 USD +0,77 USD +0,53 %
BTT
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.12,33 Mrd. EUR

KGV41,47Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Dis...
PR NewswireNeurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
BenzingaWhere Neurocrine Biosciences Stands With Analysts
Wer­bungNeurocrine Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireNeurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
BenzingaBreaking Down Neurocrine Biosciences: 12 Analysts Share Their Views
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in September
PR NewswireNeurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
BenzingaThe Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts
ZacksNeurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
PR NewswireNeurocrine Biosciences Reports Second Quarter 2025 Financial Results
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
PR NewswireNeurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
PR NewswireNeurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Co...
PR NewswireNeurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
PR NewswireNeurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
BenzingaA Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
PR NewswireNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Diseas...
PR NewswireNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dysk...
PR NewswireNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
PR NewswireNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive ...
PR NewswireNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
PR NewswireNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
PR NewswireNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY...
PR NewswireNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improv...
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in May
PR NewswireNeurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
BenzingaWhat 19 Analyst Ratings Have To Say About Neurocrine Biosciences
ZacksNeurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
PR NewswireNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
PR NewswireNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
ZacksNeurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?
PR NewswireNeurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of C...
BenzingaWhat 16 Analyst Ratings Have To Say About Neurocrine Biosciences
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
ZacksImplied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.